Xoma and Servier sign manufacturing deal with B-Ingelheim for gevokizumab
This article was originally published in Scrip
Executive Summary
Xoma and Les Laboratoires Servier, its partner for the Phase III uveitis drug gevokizumab, have entered into a manufacturing agreement with Boehringer Ingelheim to manufacture the novel interleukin 1-beta (IL-1b) allosteric modulating antibody.